Liquid Biopsy in the Approach of Non-communicable Chronic Diseases (NCCD) and Cancer
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 1438
Special Issue Editor
Special Issue Information
Dear Colleagues,
Liquid biopsy refers to a non-invasive diagnostic technique that involves the detection and analysis of biomarkers, such as circulating tumor DNA (ctDNA), circulating RNA (cRNA), circulating tumor cells (CTCs), and exosomes, in liquid biological samples such as blood, urine, tears and saliva. Liquid biopsy is thus a new tool in understanding the mechanisms of health and disease, advising the precision medicine field. The technique has gained significant attention in recent years, particularly in the field of oncology, for its potential to detect cancer at an early stage, monitor treatment response, and predict disease recurrence. This approach aims to provide greater accuracy in its diagnosis, with the least possible discomfort to the patient at the time of collection and also complement and/or replace tissue biopsy. The application of liquid biopsy can also serve to outline strategies in the complications of chronic non-transmissible diseases. Worldwide, premature mortality from chronic non-communicable diseases (NCDs) accounted for approximately 44% of all deaths caused by these diseases, data that show the impact of this group of diseases on patients aged 30 to 69 years. Predicting, evaluating and providing conditions for decision-making based on biomarkers obtained by liquid biopsy in easily obtainable biological matrices can be a new way to contribute in the laboratory to early diagnosis and also to outline strategies for the promotion and prevention of future damage and early deaths. Therefore, we invite you to contribute to this Special Issue, which aims to show the use of different biological matrices, new physical–chemical methods applied to detect markers and even new approaches to established markers for chronic non-transmissible diseases and cancer. Pre-clinical and clinical studies will be evaluated for the aforementioned purpose.
Dr. Fernando Luiz Affonso Fonseca
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biomarkers
- alternative biological matrices
- laboratory nethods
- precision medicine
- liquid biopsy
- cancer
- non-communicable chronic diseases
- clinical studies
- preclinical studies
